Based on the randomized clinical trials, which showed a significant survival benefit of the combination of tamoxifen plus LH-RH agonist [10–12], the combination has been used as a postoperative adjuvant therapy for premenopausal women with endocrine-responsive early breast cancer [13]. Here, GNRH1 is linked to breast carcinoma.